

Teprotumumab

Cat. No.:	HY-P99165
CAS No.:	1036734-93-6
Molecular Weight:	145.671 kDa
Target:	IGF-1R; TSH Receptor
Pathway:	Protein Tyrosine Kinase/RTK; GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α -subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research ^[1] .
In Vitro	Teprotumumab (0-500 μ g/mL, 12 h) attenuates the actions of both IGF-1 and TSH in fibrocytes. IGF-1R and TSHR mRNA abundance is unaffected by Teprotumumab after 24 hours ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Clin Invest. 2025 Jan 16;135(2):e178198.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Chen H, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014 Sep;99(9):E1635-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA